当前位置: 首页 > 期刊 > 《中国医学创新》 > 2012年第14期 > 正文
编号:12280033
心可舒胶囊配伍厄贝沙坦片治疗高血压左室肥厚心肌缺血的临床研究(1)
http://www.100md.com 2012年5月15日 张乃奇
第1页

    参见附件。

     【摘要】 目的:探讨心可舒胶囊配伍厄贝沙坦片治疗高血压左室肥厚心肌缺血的疗效与安全性。方法:将96例高血压左室肥厚心肌缺血患者分为观察组与对照组,每组各48例。对照组予以缬沙坦与非洛地平片治疗,观察组予以厄贝沙坦片与心可舒胶囊治疗。两组均规律治疗6个月,治疗前后评定患者血压、心肌缺血、左室肥厚的变化,记录治疗过程中的不良反应。结果:治疗后,两组患者的血压均较治疗前降低,且观察组优于对照组;观察组与对照组的心肌缺血改善总有效率分别为93.75%、81.25%;观察组治疗后,IVST、PWT、LVD、LVMI均较治疗前缩小,左室肥厚逆转效果优于对照组,上述指标差异均具有统计学意义(P<0.05或P<0.01)。两组不良反应发生率分别为4.17%、6.25%,差异无统计学意义(P>0.05)。结论:心可舒胶囊配伍厄贝沙坦片治疗高血压左室肥厚心肌缺血疗效显著,可显著降低患者的血压水平,改善心肌缺血状态,逆转心肌重构,未见明显的不良反应,值得在基层医疗机构中推广应用。

    【关键词】 高血压; 心肌缺血; 左室肥厚; 厄贝沙坦; 心可舒胶囊

    Clinical Research of Xinkeshu Capsule Combined with Irbesartan tablets in Treatment of Myocardial Ischemia Caused by Hypertensive Left Ventricular Hypertrophy/ZHANG Nai-qi.//Medical Innovation of China,2012,9(14):008-010

    【Abstract】 Objective:To explore the clinical efficacy and safety of Xinkeshu capsule combined with Irbesartan tablets in treatment of myocardial ischemia caused by hypertensive left ventricular hypertrophy (LVH).Methods:96 cases with myocardial ischemia causing by hypertensive LVH were divided into observation group and control group, 48cases in each group. Patients in control group were given valsartan and felodipine, and patients in observation group were given Xinkeshu capsule and Irbesartan tablets. Patients in two groups were all treated for 6 months, then their blood pressure, myocardial ischemia, left ventricular hypertrophy were assessed before and after treatment. And adverse reactions were noted during treatment. Results:All patients’ BP were reduced after treatment, and observation group’s effect were better than that in control group. Total improvement rate on treating myocardial ischemia were 93.75% and 81.25% respectively in two groups. IVST,PWT,LVD and LVMI in observation group were decreased, and the observation group’s effect on reversing LVH was better than that of control group. There were statistical difference between above indicators(P<0.05 or P<0.01). Adverse reaction rates in observation group and control group were 4.17% and 6.25%, and there were no statistical difference (P>0.05). Conclusion: Xinkeshu capsule and Irbesartan tablets is effective in treatment of myocardial ischemia caused by hypertensive LVH, and it can decrease BP’s level significantly,improve myocardial ischemia,reverse myocardial remodeling,and yet has no obvious adverse reaction ......

您现在查看是摘要介绍页,详见PDF附件(3818kb)